Fig. 8
From: RETRACTED ARTICLE: Vasculogenic mimicry formation in EBV-associated epithelial malignancies
Synergistic effects of PX-478 and Axitinib in NPC-EBV. a Image of CNE2-EBV xenograft tumors from mice treated with vehicle, Axitinib alone (30 mg kg−1 p.o., twice a day), PX-478 (5 mg kg−1 p.o., every 2 days) alone or Axitinib plus PX-478. b Growth curves of CNE2-EBV xenograft tumors after treatment with vehicle, Axitinib or/and PX-478. Mean ± SD, n = 10, ***p < 0.001 versus the other three treatment groups (two-tailed Mann–Whitney test). c H&E, PAS and mouse CD31 staining of CNE2-EBV xenograft sections. Red lines: necrotic area. White scale bars = 100 μm, black scale bars = 50 μm. d Numbers of endothelial cell (EC) channel-like structures in CNE2-EBV xenograft tumors from mice treated with vehicle, Axitinib or/and PX-478. Channels were determined under a microscope with 400× magnification in randomly chosen fields. Mean ± SD, n = 5, two-tailed Mann–Whitney test. e Number of VM channel-like structures in CNE2-EBV xenografts counted as in d. f Working model illustrating the mechanism by which EBV promotes VM and the aggressiveness of carcinomas such as NPC and EBVaGC. ns: not significant, *p < 0.05, ***p < 0.001
